Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-03-28 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares (限售股) of a company after its initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period, shareholder commitments, and regulatory approvals. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It does not contain financial statements or detailed financial performance data but focuses on share circulation and shareholder commitments related to the IPO. The document length is about 5899 characters, which is sufficient for a detailed announcement but not a full financial report. This type of document fits the category of Share Issue/Capital Change (SHA), as it announces the change in share capital availability due to the unlocking and listing of restricted shares post-IPO.
2024-03-28 Chinese
科美诊断技术股份有限公司关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company regarding the postponement of certain investment projects funded by proceeds from its initial public offering (IPO). It details the original and adjusted completion dates of these projects, the reasons for the delay, and confirms that the changes do not affect the investment content or total amount. The document includes opinions from the board of directors, supervisory board, and the sponsoring institution, confirming compliance with regulatory requirements. There are no financial statements or detailed financial performance data presented, and the document is relatively short (3853 characters). It is not a full annual or interim report, nor an earnings release. It is a regulatory announcement about changes in the use of raised capital and project timelines, fitting the category of Capital/Financing Update (CAP).
2024-03-26 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司部分募投项目延期的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the delay in certain fundraising investment projects of Kemei Diagnostic Technology Co., Ltd. It includes specifics about the fundraising amount, project adjustments, reasons for delay, impact assessment, and approval procedures by the board and supervisory committee. The document references regulatory compliance with the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is not a simple announcement or certification but a substantive report on the status and verification of fundraising project delays. This fits the category of an Audit Report / Information (AR), as it involves audit verification and regulatory compliance review related to fundraising projects, but is not a full annual report or financial statement. The document length (3857 characters) is sufficient for a detailed report but not a full annual report. Therefore, the best classification is AR with high confidence. Q1 2024
2024-03-26 Chinese
科美诊断技术股份有限公司第二届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of a company regarding the approval of a resolution about the delay of certain fundraising projects. It includes details about the meeting, attendance, compliance with laws, and the voting results. The content is an official announcement of a board decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion. The document length is short (695 characters), and it is a formal announcement of a board resolution related to capital projects. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like Capital/Financing Update (CAP) or Management Reports (MDA).
2024-03-26 Chinese
科美诊断技术股份有限公司关于2021年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the listing and circulation of shares related to a restricted stock incentive plan. It details the decision procedures, stock allocation, registration, and impact on share capital. It includes references to board meetings, shareholder meetings, and regulatory approvals. The document is not a full financial report but an announcement about share issuance and stock incentive plan implementation. It does not contain comprehensive financial statements or detailed financial analysis. The document length is 3378 characters, which is relatively short and focused on a specific corporate action related to share issuance and capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-03-11 Chinese
科美诊断技术股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from the company's board regarding the progress of a share repurchase program. It details the number of shares repurchased, the price range, total funds used, and compliance with relevant regulations. There is no financial statement or detailed financial analysis, but rather an update on the company's buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's repurchase of its own shares.
2024-02-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.